1.AMPK: a novel target controlling inflammation.
Feng YAO ; Guang-Yan JI ; Li ZHANG
Acta Physiologica Sinica 2012;64(3):341-345
The AMP-activated protein kinase (AMPK) is a pivotal serine/threonine kinase participating in the regulation of glucose, lipid as well as protein metabolism and maintenance of energy homeostasis. Recent studies demonstrated that AMPK can also inhibit nuclear factor-κB, suppress the expression of inflammatory genes and attenuate inflammatory injury through phosphorylating its downstream targets including SIRT1, PGC-lα, p53 and FoxO3a. In addition, the widely used antidiabetic metformin also exerts its anti-inflammatory effects through activating AMPK. Therefore, AMPK is emerging as a promising novel target for the development of anti-inflammatory drugs. This review summarized the anti-inflammatory effects of AMPK and the underling molecular mechanisms.
AMP-Activated Protein Kinases
;
metabolism
;
Homeostasis
;
Inflammation
;
enzymology
;
Metformin
;
pharmacology
;
NF-kappa B
;
antagonists & inhibitors
;
Phosphorylation
2.Aging impairs insulin-stimulated glucose uptake in rat skeletal muscle via suppressing AMPKalpha.
Wan QIANG ; Kang WEIQIANG ; Zhu QING ; Zhang PENGJU ; Liu YI
Experimental & Molecular Medicine 2007;39(4):535-543
Insufficient intracellular fat oxidation is an important contributor to aging-related insulin resistance, while the precise mechanism underlying is unclear. AMP-activated protein kinase (AMPK) is an important regulator of intracellular fat oxidation and was evidenced to play a key role in high-glucose and high-fat induced glucose intolerance. In the present study, we investigated whether altered AMPK expression or activity was also involved in aging-related insulin resistance. Insulin sensitivity of rats' skeletal muscles was evaluated using in-vitro glucose uptake assay. Activity of alpha subunit of AMPK (AMPKalpha) was evaluated by measuring the phosphorylation of both AMPKalpha (P-AMPKalpha) and acetyl-CoA carboxylase (P-ACC), while expression of AMPKalpha was assessed by determining the mRNA levels of AMPKalpha1 and AMPKalpha2, and protein contents of AMPKalpha. Compared with 4-month old rats, 24-month old rats exhibited obviously impaired insulin sensitivity. At the same time, AMPKalpha activity significantly decreased, while AMPKalpha expression did not alter during aging. Glucose transporter 4 expression also decreased in old rats. Compared with 24-month old rats, administration of the specific activator of AMPK, 5-aminoimidazole-4-carboxamide riboside (AICAR), significantly elevated AMPKalpha activity and GluT4 expression. Also, aging-related insulin resistance was significantly ameliorated by AICAR treatment. In conclusion, aging-related insulin resistance is associated with impaired AMPKalpha activity and could be ameliorated by AICAR, thus indicating a possible role of AMPK in aging-induced insulin resistance.
AMP-Activated Protein Kinases
;
Acetyl-CoA Carboxylase/metabolism
;
Aging/*physiology
;
Aminoimidazole Carboxamide/analogs & derivatives/pharmacology
;
Animals
;
Glucose/*metabolism
;
Glucose Transporter Type 4/metabolism
;
Insulin/*blood
;
*Insulin Resistance
;
Male
;
Multienzyme Complexes/*antagonists & inhibitors/metabolism
;
Muscle, Skeletal/*metabolism
;
Phosphorylation
;
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
;
Rats
;
Rats, Wistar
;
Ribonucleotides/pharmacology
3.Enhancement of hypoxia tolerance and survival rate of Daphnia in severe hypoxia based on acidic preconditioning.
Peng FU ; Bo SHENG ; Guohua LI
Journal of Biomedical Engineering 2012;29(6):1160-1167
pH homeostasis is essential for development, proliferation and apoptosis of cells. Once the pH balances are broken, cell functions and survival will be affected. Nevertheless, moderate acidosis could result in adaptive responses for cell survival and increase tolerance to harmful stress. Here we found that acidic preconditioning (APC) could significantly increase the survival rate of Daphnia pulex, a freshwater invertebrate, during severe hypoxic insult. Meanwhile, the acidic treatment significantly increased the gene expression of hypoxia inducible factor (HIF). Both echinomycin, an inhibitor of HIF, and compound C, an inhibitor of AMP-activated protein kinase (AMPK), could effectively eliminate the acid-induced hypoxic tolerance and the enhanced transcription of HIF. Temsirolimus, an inhibitor of mammalian Target of Rapamycin (mTOR), though effectively abolished the increased transcription of HIF, improved the APC-mediated protection. This result suggests that the involvement of the HIF and AMPK and mTOR could signal the pathways in APC-induced protection against hypoxic insult.
AMP-Activated Protein Kinases
;
antagonists & inhibitors
;
Acids
;
pharmacology
;
Adaptation, Physiological
;
Animals
;
Daphnia
;
genetics
;
physiology
;
Hypoxia
;
physiopathology
;
Hypoxia-Inducible Factor 1
;
genetics
;
metabolism
;
Ischemic Preconditioning
;
methods
;
Pyrazoles
;
pharmacology
;
Pyrimidines
;
pharmacology
;
RNA, Messenger
;
genetics
;
metabolism
;
Sirolimus
;
analogs & derivatives
;
pharmacology
;
TOR Serine-Threonine Kinases
;
antagonists & inhibitors
4.The death pathway of oligodendrocyte precursor cell induced by either ischemia or infection.
Chinese Journal of Contemporary Pediatrics 2008;10(4):569-572
AMP-Activated Protein Kinases
;
Animals
;
Antioxidants
;
pharmacology
;
Apoptosis
;
drug effects
;
Humans
;
Infant, Newborn
;
Infection
;
pathology
;
Ischemia
;
pathology
;
Leukomalacia, Periventricular
;
etiology
;
Multienzyme Complexes
;
physiology
;
Nitric Oxide Synthase Type II
;
antagonists & inhibitors
;
Oligodendroglia
;
cytology
;
Protein-Serine-Threonine Kinases
;
physiology
;
Reactive Oxygen Species
;
metabolism
;
Stem Cells
;
cytology
5.Rolipram, a Phosphodiesterase 4 Inhibitor, Stimulates Inducible cAMP Early Repressor Expression in Osteoblasts.
Eun Sook CHO ; Ja Heon YU ; Mi Sun KIM ; Mijung YIM
Yonsei Medical Journal 2005;46(1):149-154
Phosphodiesterase (PDE) 4 inhibitors have been shown to induce the cAMP-mediated signaling pathway by inhibiting cAMP hydrolysis. This study investigated the effect of a PDE4 inhibitor on the expression of the inducible cAMP early repressor (ICER), which is an endogenous inhibitor of CRE- mediated transcription, in osteoblastic cells. RT-PCR analysis revealed that rolipram, a PDE4 inhibitor, stimulates the ICER mRNA in a dose dependent manner. The induction of ICER mRNA expression by rolipram was suppressed by the inhibitors of protein kinase A (PKA) and p38 MAPK, suggesting the involvement of PKA and p38 MAPK activation in ICER expression by rolipram. It was previously shown that rolipram induced the expression of TNF-related activation-induced cytokine (TRANCE, also known as RANKL, ODF, or OPGL) in osteoblasts. This paper provides evidences that a transcriptional repressor like ICER might modulate TRANCE mRNA expression by rolipram in osteoblasts.
3', 5'-Cyclic-Nucleotide Phosphodiesterase/*antagonists & inhibitors
;
Animals
;
Animals, Outbred Strains
;
Cyclic AMP-Dependent Protein Kinases/metabolism
;
DNA-Binding Proteins/genetics/*metabolism
;
Gene Expression/drug effects
;
Mice
;
Osteoblasts/*drug effects/metabolism
;
Phosphodiesterase Inhibitors/*pharmacology
;
Research Support, Non-U.S. Gov't
;
Rolipram/*pharmacology
;
Transcription Factors/genetics/*metabolism
;
p38 Mitogen-Activated Protein Kinases/metabolism
6.Cilostazol Protects Endothelial Cells Against Lipopolysaccharide-Induced Apoptosis Through ERK1/2- and P38 MAPK-Dependent Pathways.
Jong Hoon LIM ; Jae Suk WOO ; Yung Woo SHIN
The Korean Journal of Internal Medicine 2009;24(2):113-122
BACKGROUND/AIMS: We examined the effects of cilostazol on mitogen-activated protein kinase (MAPK) activity and its relationship with cilostazol-mediated protection against apoptosis in lipopolysaccharide (LPS)-treated endothelial cells. METHODS: Human umbilical vein endothelial cells (HUVECs) were exposed to LPS and cilostazol with and without specific inhibitors of MAPKs; changes in MAPK activity in association with cell viability and apoptotic signaling were investigated. RESULTS: Cilostazol protected HUVECs against LPS-induced apoptosis by suppressing the mitochondrial permeability transition, cytosolic release of cytochrome c, and subsequent activation of caspases, stimulating extracellullar signal-regulated kinase (ERK1/2) and p38 MAPK signaling, and increasing phosphorylated cAMPresponsive element-binding protein (CREB) and Bcl-2 expression, while suppressing Bax expression. These cilostazol-mediated cellular events were effectively blocked by MAPK/ERK kinase (MEK1/2) and p38 MAPK inhibitors. CONCLUSIONS: Cilostazol protects HUVECs against LPS-induced apoptosis by suppressing mitochondriadependent apoptotic signaling. Activation of ERK1/2 and p38 MAPKs, and subsequent stimulation of CREB phosphorylation and Bcl-2 expression, may be responsible for the cellular signaling mechanism of cilostazolmediated protection.
Apoptosis/*drug effects
;
Caspases/metabolism
;
Cell Line
;
Cell Survival/drug effects
;
Cyclic AMP Response Element-Binding Protein/metabolism
;
Cytochromes c/metabolism
;
Dose-Response Relationship, Drug
;
Endothelial Cells/*drug effects/enzymology/pathology
;
Humans
;
Lipopolysaccharides/*toxicity
;
Mitochondrial Membrane Transport Proteins/drug effects/metabolism
;
Mitogen-Activated Protein Kinase 1/antagonists & inhibitors/*metabolism
;
Mitogen-Activated Protein Kinase 3/antagonists & inhibitors/*metabolism
;
Phosphodiesterase Inhibitors/*pharmacology
;
Phosphorylation
;
Protein Kinase Inhibitors/pharmacology
;
Proto-Oncogene Proteins c-bcl-2/metabolism
;
Signal Transduction/*drug effects
;
Tetrazoles/*pharmacology
;
Time Factors
;
bcl-2-Associated X Protein/metabolism
;
p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism
7.The effect of 5-aminoimidazole-4-carboxamide-ribonucleoside was mediated by p38 mitogen activated protein kinase signaling pathway in FRO thyroid cancer cells.
Won Gu KIM ; Hyun Jeung CHOI ; Tae Yong KIM ; Young Kee SHONG ; Won Bae KIM
The Korean Journal of Internal Medicine 2014;29(4):474-481
BACKGROUND/AIMS: 5'-Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a cellular energy sensor that monitors intracellular AMP/adenosine triphosphate (ATP) ratios and is a key regulator of the proliferation and survival of diverse malignant cell types. In the present study, we investigated the effect of activating AMPK by 5-aminoimidazole-4-carboxamide-ribonucleotide (AICAR) in thyroid cancer cells. METHODS: We used FRO thyroid cancer cells harboring the BRAF(V600E) mutation to examine the effect of AICAR on cell proliferation and cell survival. We also evaluated the involvement of mitogen-activated protein kinase (MAPK) pathways in this effect. RESULTS: We found that AICAR treatment promoted AMPK activation and suppressed cell proliferation and survival by inducing p21 accumulation and activating caspase-3. AICAR significantly induced activation of p38 MAPK, and pretreatment with SB203580, a specific inhibitor of the p38 MAPK pathway, partially but significantly rescued cell survival. Furthermore, small interfering RNA targeting AMPK-alpha1 abolished AICAR-induced activation of p38 MAPK, p21 accumulation, and activation of caspase-3. CONCLUSIONS: Our findings demonstrate that AMPK activation using AICAR inhibited cell proliferation and survival by activating p38 MAPK and proapoptotic molecules in FRO thyroid cancer cells. These results suggest that the AMPK and p38 MAPK signaling pathways may be useful therapeutic targets to treat thyroid cancer.
AMP-Activated Protein Kinases/genetics/metabolism
;
Aminoimidazole Carboxamide/*analogs & derivatives/pharmacology
;
Antineoplastic Agents/*pharmacology
;
Caspase 3/metabolism
;
Cell Line, Tumor
;
Cell Proliferation/drug effects
;
Cell Survival/drug effects
;
Cyclin-Dependent Kinase Inhibitor p21/metabolism
;
Dose-Response Relationship, Drug
;
Enzyme Activation
;
Enzyme Activators/pharmacology
;
Humans
;
Mutation
;
Protein Kinase Inhibitors/pharmacology
;
Proto-Oncogene Proteins B-raf/genetics
;
RNA Interference
;
Ribonucleotides/*pharmacology
;
Signal Transduction/*drug effects
;
Thyroid Neoplasms/*enzymology/genetics/pathology
;
Time Factors
;
Transfection
;
p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism
8.AMPK interacts with DSCAM and plays an important role in netrin-1 induced neurite outgrowth.
Kun ZHU ; Xiaoping CHEN ; Jianghong LIU ; Haihong YE ; Li ZHU ; Jane Y WU
Protein & Cell 2013;4(2):155-161
Down syndrome cell adhesion molecule (DSCAM) acts as a netrin-1 receptor and mediates attractive response of axons to netrin-1 in neural development. However, the signaling mechanisms of netrin-DSCAM remain unclear. Here we report that AMP-activated protein kinase (AMPK) interacts with DSCAM through its γ subunit, but does not interact with DCC (deleted in colorectal cancer), another major receptor for netrin-1. Netrin-treatment of cultured cortical neurons leads to increased phosphorylation of AMPK. Both AMPK mutant with dominant-negative effect and AMPK inhibitor can significantly suppress netrin-1 induced neurite outgrowth. Together, these findings demonstrate that AMPK interacts with DSCAM and plays an important role in netrin-1 induced neurite outgrowth. Our study uncovers a previously unknown component, AMPK, in netrin-DSCAM signaling pathway.
AMP-Activated Protein Kinases
;
antagonists & inhibitors
;
genetics
;
metabolism
;
Animals
;
Cell Adhesion Molecules
;
genetics
;
metabolism
;
Cells, Cultured
;
HEK293 Cells
;
Humans
;
Mice
;
Nerve Growth Factors
;
pharmacology
;
Netrin-1
;
Neurites
;
physiology
;
Neurons
;
cytology
;
drug effects
;
metabolism
;
Phosphorylation
;
Protein Binding
;
Protein Kinase Inhibitors
;
pharmacology
;
RNA Interference
;
RNA, Small Interfering
;
Recombinant Fusion Proteins
;
biosynthesis
;
genetics
;
Signal Transduction
;
drug effects
;
Transfection
;
Tumor Suppressor Proteins
;
pharmacology
9.AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin.
Yun Kyoung LEE ; Song Yi PARK ; Young Min KIM ; Won Sup LEE ; Ock Jin PARK
Experimental & Molecular Medicine 2009;41(3):201-207
AMPK (AMP-activated protein kinase) is highly conserved in eukaryotes, where it functions primarily as a sensor of cellular energy status. Recent studies indicate that AMPK activation strongly suppresses cell proliferation in non-malignant cells as well as in tumor cells. In this study, quercetin activated AMPK in MCF breast cancer cell lines and HT-29 colon cancer cells, and this activation of AMPK seemed to be closely related to a decrease in COX-2 expression. The application of a COX-2 inhibitor or cox-2(-/-) cells supported the idea that AMPK is an upstream signal of COX-2, and is required for the anti-proliferatory and pro-apoptotic effects of quercetin. The suppressive or growth inhibitory effects of quercetin on COX-2 were abolished by treating cancer cells with an AMPK inhibitor Compound C. These results suggest that AMPK is crucial to the anti-cancer effect of quercetin and that the AMPK-COX-2 signaling pathway is important in quercetin-mediated cancer control.
AMP-Activated Protein Kinases/antagonists & inhibitors/*physiology
;
Anticarcinogenic Agents/*pharmacology
;
Antioxidants/*pharmacology
;
Apoptosis/*drug effects
;
Cell Cycle/drug effects/physiology
;
Cell Line, Tumor
;
Cell Proliferation/*drug effects
;
Cyclooxygenase 2/genetics/*physiology
;
Cyclooxygenase 2 Inhibitors/pharmacology
;
Enzyme Activation
;
Humans
;
Pyrazoles/pharmacology
;
Pyrimidines/pharmacology
;
Quercetin/*pharmacology
10.Globular adiponectin protects human umbilical vein endothelial cells against apoptosis through adiponectin receptor 1/adenosine monophosphate-activated protein kinase pathway.
Hong-Yu ZHAO ; Min ZHAO ; Tong-Ning YI ; Jin ZHANG
Chinese Medical Journal 2011;124(16):2540-2547
BACKGROUNDEndothelial dysfunction is a key event in the onset and progression of atherosclerosis in diabetic patients. Apoptosis may lead to endothelial dysfunction and contribute to vascular complications. However, no study has addressed apoptosis in human umbilical vein endothelial cells (HUVECs) induced by an intermittent high-glucose media and its association with adiponectin receptor 1 (adipoR1), adipoR2, or adenosine monophosphate (AMP)-activated protein kinase (AMPK).
METHODSHUVECs were cultured in continuous normal glucose (5.5 mmol/L), continuous high glucose (25 mmol/L), alternating normal and high glucose and mannitol. In the alternating normal and high-glucose media, HUVECs were treated under different conditions. First, cells were transfected with the adipoR1-specific small-interfering RNA (siRNA) and then stimulated with globular adiponectin (gAD). Second, cells were cultured in both gAD and the AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR). Third, cells were cultured in the AMPK inhibitor adenine-9-β-D-arabino-furanoside (araA), gAD, and in AICAR.
RESULTSHUVEC apoptosis increased more significantly in an intermittent high-glucose medium than in a constant high-glucose medium. HUVEC apoptosis induced by an intermittent high-glucose medium was inhibited when the cells were pretreated with 3 µg/ml gAD, which rapidly activated AMPK and adipoR1 in HUVECs. However, adipoR2 was not activated.
CONCLUSIONSWe found that adipoR1, not adipoR2, is involved in mediating intermittent high-concentration glucose-evoked apoptosis in endothelial cells. gAD activated AMPK through adipoR1, leads to the partial inhibition of HUVEC apoptosis. A fluctuating glucose medium is more harmful than a constant high-glucose medium to endothelial cells.
AMP-Activated Protein Kinases ; antagonists & inhibitors ; genetics ; metabolism ; Adiponectin ; pharmacology ; Aminoimidazole Carboxamide ; analogs & derivatives ; pharmacology ; Apoptosis ; drug effects ; Glucose ; pharmacology ; Human Umbilical Vein Endothelial Cells ; cytology ; drug effects ; metabolism ; Humans ; RNA, Small Interfering ; Receptors, Adiponectin ; genetics ; metabolism ; Ribonucleotides ; pharmacology ; Signal Transduction ; drug effects ; genetics